Display options
Cite
Kus T, Aktas G, Sevinc A, et al. Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?. Onco Targets Ther. 2015;8:1341-3doi: 10.2147/OTT.S84480.
Kus, T., Aktas, G., Sevinc, A., Kalender, M. E., & Camci, C. (2015). Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?. OncoTargets and therapy, 81341-3. https://doi.org/10.2147/OTT.S84480
Kus, Tulay, et al. "Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?." OncoTargets and therapy vol. 8 (2015): 1341-3. doi: https://doi.org/10.2147/OTT.S84480
Kus T, Aktas G, Sevinc A, Kalender ME, Camci C. Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?. Onco Targets Ther. 2015 Jun 05;8:1341-3. doi: 10.2147/OTT.S84480. eCollection 2015. PMID: 26150726; PMCID: PMC4485179.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2015 Jun 05;8:1341-3. doi: 10.2147/OTT.S84480. eCollection 2015.

Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?.

OncoTargets and therapy

Tulay Kus, Gokmen Aktas, Alper Sevinc, Mehmet Emin Kalender, Celaletdin Camci

Affiliations

  1. Department of Internal Medicine, Division of Medical Oncology, Gaziantep University, Gaziantep, Turkey.

PMID: 26150726 PMCID: PMC4485179 DOI: 10.2147/OTT.S84480

Abstract

Erlotinib, an epidermal growth factor receptor and tyrosine kinase inhibitor, is a targeted drug that was approved for the treatment of non-small-cell lung cancers and pancreatic cancers. Targeted tyrosine kinase inhibitors are known to have cardiotoxic effects. However, erlotinib does not have a statistically proven effect of increasing acute cardiovascular event (ACE) risk. Preclinical studies showed that beta agonist stimulation among rats that were administered erlotinib led to cardiovascular damage. Thus, there would be an aggregate effect of erlotinib on ACE, although it is not thought to be a cardiotoxic drug itself. In this paper, we present two non-small-cell lung cancer cases that developed ACE under erlotinib treatment.

Keywords: EGFR; erlotinib; lung cancer; myocardial infarction

References

  1. Med Sci Monit. 2014 Dec 15;20:2666-76 - PubMed
  2. Circulation. 2008 Jul 1;118(1):84-95 - PubMed
  3. N Engl J Med. 2005 Jul 14;353(2):172-87 - PubMed
  4. Oncology (Williston Park). 2007 Dec;21(14):1696-706; discussion 1706-9, 1712, 1715 - PubMed
  5. Int J Cardiol. 2010 Sep 24;144(1):3-15 - PubMed
  6. J Clin Oncol. 2000 Apr;18(8):1725-32 - PubMed
  7. N Engl J Med. 2005 Jul 14;353(2):123-32 - PubMed
  8. Ann Oncol. 2012 Jul;23 (7):1672-9 - PubMed
  9. J Clin Invest. 2007 Sep;117(9):2445-58 - PubMed
  10. Nat Rev Cancer. 2007 May;7(5):332-44 - PubMed
  11. J Clin Oncol. 2010 May 1;28(13):2280-5 - PubMed

Publication Types